

Health and Wellbeing Board

1. Reference Information

Paper tracking information	
Title:	Surrey Pharmaceutical Needs Assessment Supplementary Statement 2020
Related Health and Wellbeing Priority:	Statutory responsibility of the HWBB
Author (Name, post title and telephone number):	Julie George, Consultant in Public Health, 0781 353 8903
Sponsor:	Ruth Hutchinson, Interim Director of Public Health
Paper date:	5 March 2020
Version:	1.0
Related papers	2018 Pharmaceutical Needs Assessment (PNA) and 2019 PNA Supplementary statement. Available on www.surrey-i.gov.uk

2. Executive summary

The Surrey Health and Wellbeing Board (HWB) has a statutory responsibility to deliver a Pharmaceutical Needs Assessment (PNA) every three years. The Surrey PNA was last published in March 2018, but the PNA Steering Group reviews changes to the local population and local services annually to ensure no substantive changes to the PNA are required. The attached report (**Annex 1**) provides a supplementary statement to the 2018 PNA which finds no substantive changes to findings of the 2018 PNA are required.

3. Recommendations

1. The Board is asked to approve the 2020 PNA Supplementary Statement, on the advice of the PNA Steering Group.
2. The Board is asked to publish the approved Supplementary Statement on surrey-i.gov.uk and surreycc.gov.uk by 31st March 2020.

4. Reason for Recommendations

The Surrey PNA Steering Group has met to discuss findings in the 2020 PNA Supplementary Statement and have agreed the supplementary statement for approval and publication by the Health and Wellbeing Board.

5. Detail

Policy and Governance Framework

Health and Wellbeing Boards were given responsibility from 2013 for delivering a Pharmaceutical Needs Assessment (PNA) for their area. The PNA determines the local need for pharmaceutical services. The PNA is used principally to inform decisions on whether to allow new pharmaceutical services in a given area (a process called market entry) based on that need. NHS England is responsible for those commissioning

decisions. The Surrey PNA, which uses Integrated Care Partnership geographies, can also be used to support the work of local clinical commissioning groups around primary care, management of long-term conditions and urgent and emergency care.

The NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations 2013 sets out the legislative basis for developing and updating PNAs. HWBs are required to publish a revised assessment within 3 years of publication of their first assessment. In Surrey, the first PNA after these regulations was published in March 2015 and the second in March 2018, so the next full PNA must be published by April 2021.

Pending the publication of the 2021 PNA, the HWB may publish a supplementary statement explaining changes to the availability of pharmaceutical services since the publication of its PNA where those changes are relevant to the granting of applications and the HWB is satisfied that making a revised statement would be a disproportionate response to those changes. The supplementary statement becomes part of the PNA. In Surrey, we review the PNA yearly to determine if a full revision of the PNA is required and, if not, publish a supplementary statement.

The Surrey HWB delegated responsibility for delivering the Surrey Pharmaceutical Needs Assessment (PNA) to the PNA Steering Group, now chaired by Dr Julie George, Public Health Consultant.

The responsibilities of the PNA Steering Group are:

- a) Ensure the PNA project objectives are clear, defined in the PNA Project Initiation Document (PID), for the initial PNA and PNA revisions
- b) Provide executive approval and sign off of high-level project documentation and plans for the PNA project
- c) Agree quality criteria for all aspects of the PNA project
- d) Undertake executive reviews of the performance and monitor progress against plans for the PNA project
- e) Ensure the business, executive, clinical, user and technical perspectives are fully represented
- f) Resolve any conflicts between business, clinical, user and technical requirements, priorities and preferences
- g) Ensure the final products shown in the PID are delivered on schedule.
- h) Make recommendations as to agreed tolerances (with respect to time and scope) and at-risk activities
- i) Endorse sign off for each project stage and authorise continuation to the next stage as stated in the PNA PID and timeline.
- j) Ensure all relevant guidance and policies are followed, and ensure probity at all times
- k) Ensure the PNA is utilized to influence commissioning
- l) Communicate with key stakeholders about the PNA

2020 PNA Supplementary Statement

The PNA Steering Group met on 29th January 2020 to review changes to the local population and to pharmaceutical provision since the publication of the Surrey PNA 2018 and the 2019 Supplementary Statement, to determine whether there were

sufficient changes in provision of pharmaceutical need or services to require a full-scale revision to the PNA.

The Steering Group found that the changes to demographic need and pharmaceutical provision were minimal and therefore a supplementary statement detailing the changes, rather than a revision, was sufficient. The attached 2020 PNA Supplementary Statement details the changes to pharmacy provision and the other information considered as well as the conclusion reached.

2021 full PNA

The planning for the next full PNA, to be published by 1st April 2021, has started. Discussions are being held with representatives of the healthcare system, including members of the Primary Care Transformation Board, to consider how the PNA could support the aims of the NHS Long Term Plan and the primary care transformation in Surrey. Discussions with planning officers in the local District and Boroughs will also be used to inform how best to use the PNA process to support the planning of pharmacy provision for future large-scale housing developments within Surrey.

6. Challenges

The process for determining the PNA Supplementary Statement is robust so risks are minimal for this part of the process.

One issue still to be resolved for the 2021 PNA is how to deal with the tension between the way in which planning takes account of the need for health infrastructure, especially in new large-scale housing developments (needs based on future build) and the way in which the PNA determines the need for market entry for community pharmacies (need for current population). One additional challenge to delivery of the 2021 PNA is securing the required data in a timely way.

7. Timescale and delivery plan

An outline plan for delivery of the 2021 PNA has been developed and will be revised if necessary based on discussions with local healthcare partners. The draft report should be completed by September 2020 with consultation on the report during October and November, any redrafting required by the feedback during December with the PNA Steering Group considering the final report in January 2021. The final report will be brought to the HWBB for approval by March 2021 latest.

8. How is this being communicated?

The Health and Wellbeing Board Communications Group have been advised about the consultation on the 2021 PNA.

9. Next steps

If the HWBB approves the 2020 Supplementary Statement, it will be published by 31st March on surreycc.gov.uk and surreyi.gov.uk websites.

The PNA Steering Group will meet at critical points in the delivery of the 2021 PNA to approve action to date and escalate any issues. If the HWBB wishes a report on progress during the year, a report can be provided to the Board.

This page is intentionally left blank